AKTS · Aktis Oncology Inc. Common stock
View on chartInsiders & Stakes
| Ansbert Gadicke Director | ▲ Buy | Open Market | 10,260,064 Shares held | 1/12/2026 | View profile |
| MPM BIOVENTURES 2018, L.P. 10% Owner | ▲ Buy | Open Market | 10,260,064 Shares held | 1/12/2026 | View profile |
| Foley Todd Director | ▲ Buy | Open Market | 4,235,403 Shares held | 1/12/2026 | View profile |
| EcoR1 Capital, LLC 10% Owner | ▲ Buy | Open Market | 347,305 Shares held | 1/12/2026 | View profile |
| Vida Ventures II, LLC | ▲ Buy | Open Market | 157,387 Shares held | 1/12/2026 | View profile |
| Kim Helen Susan | ▲ Buy | Open Market | 157,387 Shares held | 1/12/2026 | View profile |
| Segal Lloyd Mitchell | ▼ Sell | Other | 19,631 Shares held | 1/12/2026 | View profile |
| Herrmann Ken | ▼ Sell | Open Market | 0 Shares held | 7/20/2026 | View profile |
| Ron-Bigger Shulamit Chief Operating Officer | ▼ Sell | Open Market | 0 Shares held | 7/8/2026 | View profile |
| Czibere Akos Chief Medical Officer | ▼ Sell | Open Market | 0 Shares held | 9/23/2026 | View profile |
Transaction History
| Czibere Akos | ▲ Buy | Option Exercise | 12,500 | $62K | 9/23/2026 |
| Czibere Akos | ▼ Sell | Open Market | 5,099 | $103K | 9/23/2026 |
| Czibere Akos | ▼ Sell | Open Market | 7,401 | $156K | 9/23/2026 |
| Herrmann Ken | ▲ Buy | Option Exercise | 3,506 | $280 | 7/20/2026 |
| Herrmann Ken | ▲ Buy | Option Exercise | 1,350 | $3K | 7/20/2026 |
| Herrmann Ken | ▼ Sell | Open Market | 3,506 | $86K | 7/20/2026 |
| Herrmann Ken | ▼ Sell | Open Market | 1,350 | $33K | 7/20/2026 |
| Herrmann Ken | ▲ Buy | Option Exercise | 3,065 | $245 | 7/17/2026 |
| Herrmann Ken | ▼ Sell | Open Market | 3,065 | $77K | 7/17/2026 |
| Ron-Bigger Shulamit | ▲ Buy | Option Exercise | 50,000 | $183K | 7/8/2026 |
| Ron-Bigger Shulamit | ▼ Sell | Open Market | 15,800 | $429K | 7/8/2026 |
| Ron-Bigger Shulamit | ▼ Sell | Open Market | 30,000 | $838K | 7/8/2026 |
| Ron-Bigger Shulamit | ▼ Sell | Open Market | 4,200 | $121K | 7/8/2026 |
| Czibere Akos | ▲ Buy | Option Exercise | 50,000 | $248K | 7/8/2026 |
| Czibere Akos | ▼ Sell | Open Market | 14,800 | $401K | 7/8/2026 |
| Czibere Akos | ▼ Sell | Open Market | 30,829 | $862K | 7/8/2026 |
| Czibere Akos | ▼ Sell | Open Market | 4,371 | $125K | 7/8/2026 |
| EcoR1 Capital, LLC | ▼ Sell | Other | 128,506 | — | 1/12/2026 |
| Foley Todd | ▼ Sell | Other | 597,391 | — | 1/12/2026 |
| Foley Todd | ▼ Sell | Other | 2,688,270 | — | 1/12/2026 |
| Foley Todd | ▼ Sell | Other | 716,872 | — | 1/12/2026 |
| Foley Todd | ▲ Buy | Open Market | 232,870 | $4.2M | 1/12/2026 |
| MPM BIOVENTURES 2018, L.P. | ▼ Sell | Other | 1,314,262 | — | 1/12/2026 |
| MPM BIOVENTURES 2018, L.P. | ▼ Sell | Other | 5,914,197 | — | 1/12/2026 |
| MPM BIOVENTURES 2018, L.P. | ▼ Sell | Other | 1,577,119 | — | 1/12/2026 |
| MPM BIOVENTURES 2018, L.P. | ▲ Buy | Open Market | 1,112,777 | $20.0M | 1/12/2026 |
| Ansbert Gadicke | ▼ Sell | Other | 1,314,262 | — | 1/12/2026 |
| Ansbert Gadicke | ▼ Sell | Other | 5,914,197 | — | 1/12/2026 |
| Ansbert Gadicke | ▼ Sell | Other | 1,577,119 | — | 1/12/2026 |
| Ansbert Gadicke | ▲ Buy | Open Market | 1,112,777 | $20.0M | 1/12/2026 |
| EcoR1 Capital, LLC | ▼ Sell | Other | 202,862 | — | 1/12/2026 |
| EcoR1 Capital, LLC | ▲ Buy | Open Market | 2,077,779 | $37.4M | 1/12/2026 |
| EcoR1 Capital, LLC | ▲ Buy | Open Market | 144,443 | $2.6M | 1/12/2026 |
| Vida Ventures II, LLC | ▼ Sell | Other | 4,859,370 | — | 1/12/2026 |
| Vida Ventures II, LLC | ▲ Buy | Open Market | 812,455 | $14.6M | 1/12/2026 |
| Vida Ventures II, LLC | ▼ Sell | Other | 134,842 | — | 1/12/2026 |
| Vida Ventures II, LLC | ▲ Buy | Open Market | 22,545 | $406K | 1/12/2026 |
| Kim Helen Susan | ▼ Sell | Other | 4,859,370 | — | 1/12/2026 |
| Kim Helen Susan | ▲ Buy | Open Market | 812,455 | $14.6M | 1/12/2026 |
| Kim Helen Susan | ▼ Sell | Other | 134,842 | — | 1/12/2026 |
| Kim Helen Susan | ▲ Buy | Open Market | 22,545 | $406K | 1/12/2026 |
| Segal Lloyd Mitchell | ▼ Sell | Other | 19,631 | — | 1/12/2026 |
| EcoR1 Capital, LLC | ▼ Sell | Other | 2,270,879 | — | 1/12/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AKTS launches second Phase 1b trial for AKY-2519
Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.
AKTS launches second Phase 1b trial for AKY-2519. Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.